Results 31 to 40 of about 59,116 (263)

Use of New Oral Anticoagulants/ Direct Oral Anticoagulants in Malignant Patients [PDF]

Cureus, 2020
Vitamin K antagonists are being used in the last five decades as an effective anticoagulant. However, for the past few years, new oral anticoagulants (NOACs) have been introduced as newer anticoagulant agents, which are gradually replacing the previously used vitamin K antagonist.
Khan, Yusra, Zaidi, Syed Owais, Razak, Bibi S, Zaki, Mariann, Malik, Bilal Haider   +4 more
openaire   +2 more sources

Anticoagulant therapy post-COVID in the perioperative setting: Bountiful of choices, indefinite treatment plans- A case report

Medical Journal of Dr. D.Y. Patil Vidyapeeth, 2022
A post-COVID patient with a high D-dimer Value (>5000 IU) was posted for total knee replacement. She was on multiple anticoagulants including the novel oral anticoagulants that started to reduce thrombotic risk.
Balasubramaniam Gayathri, Karthik Krishnamoorthy, Chandrakanth Lakshmikanthan, M Yuvashree   +3 more
doaj   +1 more source

Medication non‐adherence as a cause of apixaban failure in venous thromboembolism: The importance of pharmacist medication reconciliation

Clinical Case Reports, 2022
Venous thromboembolism is often treated with direct oral anticoagulants. In order for direct oral anticoagulants to be effective, patients must adhere to a specific dosing strategy.
Trisha E Jethwa, Kaitlin M Moran, Michael J Maniaci   +2 more
doaj   +1 more source

A three-year prospective study of the presentation and clinical outcomes of major bleeding episodes associated with oral anticoagulant use in the UK (ORANGE study)

Haematologica, 2018
The outcomes of patients developing major bleeding while on oral anticoagulants remain largely unquantified. The objectives of this study were to: (i) describe the burden of major hemorrhage associated with all available oral anticoagulants in terms of ...
Laura Green, Joachim Tan, Joan K Morris, Raza Alikhan, Nicola Curry, Tamara Everington, Rhona Maclean, Khalid Saja, Simon Stanworth, Campbell Tait, Peter MacCallum   +10 more
doaj   +1 more source

Safe chest tube placement in a patient with tension pneumothorax receiving rivaroxaban therapy for non-valvular atrial fibrillation

Monaldi Archives for Chest Disease, 2020
The number of patients treated with direct oral anticoagulants is increasing worldwide. Although bleeding complications associated with direct oral anticoagulants are lower than those associated with vitamin K antagonists, the increased number of ...
Alessandro Cipriano, Matteo Parollo, Ester Taurino, Elena Venturi, Massimo Santini   +4 more
doaj   +1 more source

Management of Patients Using Oral Anticoagulant Agent in Dental Practice

Bezmiâlem Science, 2019
An increasing number of patients in our country use oral anticoagulants for the prophylaxis and treatment of thromboembolic events. The cornerstone of these groups of agents is warfarin, a vitamin K antagonist, which has been the single alternative used ...
Özge DOĞANAY, Türker YÜCESOY, Alper ALKAN   +2 more
doaj   +1 more source

Oral Antithrombotic Medication Is Associated with Improved Visual Outcomes in Eyes with Submacular Hemorrhage from Wet Age-Related Macular Degeneration

Ophthalmology Science
Purpose: To determine differences in visual acuity (VA) outcomes in eyes of patients on antithrombotics (antiplatelet agents and anticoagulants) that develop submacular hemorrhage (SMH) compared with eyes of patients who are not on antithrombotics and ...
Hemal P. Patel, MD, Cason B. Robbins, MD, Jamie J. Karl, MD, Peter Weng, MD, PhD, Lejla Vajzovic, MD, FASRS, Sharon Fekrat, MD, FASRS   +5 more
doaj   +1 more source

Reversal of Oral Anticoagulation [PDF]

Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy, 2013
Although the use of dabigatran and rivaroxaban are increasing, data on the reversal of their effects are limited. The lack of reliable monitoring methods and specific reversal agents renders treatment strategies empirical, and as a result, treatment consists mainly of supportive measures.
Jonathan L, Thigpen, Nita A, Limdi
openaire   +2 more sources

Venous Thromboembolism in Pediatric Bone Sarcoma Patients: A 10‐Year, Single‐Institution Experience Encompassing the COVID‐19 Pandemic

Pediatric Blood &Cancer, EarlyView.
ABSTRACT Background Osteosarcoma (OS) and Ewing sarcoma (EWS) are the most common primary bone cancers in children, but acute thrombosis is poorly characterized in this population. Our study evaluated the rates of venous thromboembolism (VTE) and associated risk factors in pediatric patients with bone sarcomas treated over a 10‐year period encompassing
Sarah Kappa, Shou Xu, Mark Zobeck, Sarah E. Sartain, Nino Rainusso, Lisa Wang, Nicole Montgomery, Paige Wheaton, Sarah Whittle   +8 more
wiley   +1 more source

The Novel Oral Anticoagulants [PDF]

Seminars in Thrombosis and Hemostasis, 2013
After the introduction of warfarin, long-term oral anticoagulation treatment remained unchanged for more than 50 years. Most recently, with the development and approval of new oral anticoagulants, the treatment of medical conditions that require thrombosis prophylaxis and long-term anticoagulation has become more complex.
Cristhiam M, Rojas-Hernandez, David A, Garcia   +1 more
openaire   +2 more sources